TP53 and cancer: Despite their common TP53-driven genomic instability, these cancers typically exhibit low tumor mutational burden (TMB) and reduced immunogenicity, resulting in limited responses to immune checkpoint inhibitors (ICIs) [6,7,8,9,10,11].